Compare Allbirds Inc (BIRD) vs Quest Diagnostics Inc (DGX) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Allbirds Inc vs Quest Diagnostics Inc — how do they compare? Allbirds Inc trades at $2.63 (market cap $30.00M), while Quest Diagnostics Inc trades at $237.52 (market cap $26.21B). The key difference: Quest Diagnostics Inc is far larger — about 873.7× Allbirds Inc's market cap, and Quest Diagnostics Inc pays a 1.45% dividend while Allbirds Inc pays none. Which is the better fit depends on your goals.
| BIRD | DGX | |
|---|---|---|
Market Cap | $30.00M | $26.21B |
Sector | Consumer Cyclical | Health |
52-Week High | $16.99 | $238.50 |
52-Week Low | $2.21 | $173.49 |
Enterprise Value | $48.86M | $31.97B |
Dividend Yield | — | 1.45% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
BIRD trades at $2.58, up 1.98% today, amid a strategic pivot from footwear to AI infrastructure, rebranding as Smartbird. Despite negative profitability and cash burn, the stock shows bullish technical signals and surged on recent leadership changes. Revenue has declined from $298M in 2022 to $152M in 2025, with net losses persisting but improving from -$152M to -$77M over the period.
Outlook hinges on successful AI transition, but high execution risk and sustained losses warrant caution. Analysts are mostly neutral, with 79% hold ratings. The stock offers speculative upside if new strategy gains traction, yet faces significant financial and competitive headwinds.
Quest Diagnostics (DGX) trades at $237.63, down slightly by 0.3% today, but maintains strong momentum with three consecutive quarterly earnings beats and a raised 2026 outlook. The stock shows bullish technical signals with moving averages supporting upward trends, while fundamentals reveal solid revenue growth to $11.04 billion in 2025 and improving profit margins. Recent news highlights surging testing demand and AI implementation driving operational efficiency.
DGX presents a favorable investment case with analyst consensus price target of $249.50 offering 5% upside potential. Strong testing demand, strategic partnerships, and earnings momentum support growth, though elevated debt levels and margin pressures from lower-margin deals pose moderate risks. The stock's current valuation at 25.21 P/E appears reasonable given growth prospects.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Allbirds Inc
Allbirds Inc is a global lifestyle brand that innovates with naturally derived materials to make footwear and apparel products. Its primary source of revenue is from sales of shoes and apparel products in its directly owned digital and physical retail channels.
Read more on BIRD →About Quest Diagnostics Inc
Quest Diagnostics is a leading independent provider of diagnostic testing, information, and services in the U.S. The company generates over 95% of its revenue through clinical testing, anatomic pathology, esoteric testing, and substance abuse testing with specimens collected at its national network of roughly 2,300 patient service centers, as well as multiple doctors offices and hospitals. The firm also runs a much smaller diagnostic solutions segment that provides clinical trials testing, risk assessment services, and information technology solutions.
Read more on DGX →
